FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:FGFR2-ENPP2

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: FGFR2-ENPP2
FusionPDB ID: 30285
FusionGDB2.0 ID: 30285
HgeneTgene
Gene symbol

FGFR2

ENPP2

Gene ID

2263

5168

Gene namefibroblast growth factor receptor 2ectonucleotide pyrophosphatase/phosphodiesterase 2
SynonymsBBDS|BEK|BFR-1|CD332|CEK3|CFD1|ECT1|JWS|K-SAM|KGFR|TK14|TK25ATX|ATX-X|AUTOTAXIN|LysoPLD|NPP2|PD-IALPHA|PDNP2
Cytomap

10q26.13

8q24.12

Type of geneprotein-codingprotein-coding
Descriptionfibroblast growth factor receptor 2BEK fibroblast growth factor receptorbacteria-expressed kinasekeratinocyte growth factor receptorprotein tyrosine kinase, receptor like 14ectonucleotide pyrophosphatase/phosphodiesterase family member 2E-NPP 2autotaxin-textracellular lysophospholipase Dphosphodiesterase I/nucleotide pyrophosphatase 2plasma lysophospholipase D
Modification date2020032220200313
UniProtAcc

P21802

Main function of 5'-partner protein: FUNCTION: Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1. {ECO:0000269|PubMed:12529371, ECO:0000269|PubMed:15190072, ECO:0000269|PubMed:15629145, ECO:0000269|PubMed:16384934, ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:17311277, ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:18374639, ECO:0000269|PubMed:19103595, ECO:0000269|PubMed:19387476, ECO:0000269|PubMed:19410646, ECO:0000269|PubMed:21596750, ECO:0000269|PubMed:8663044}.

Q13822

Main function of 5'-partner protein: FUNCTION: Hydrolyzes lysophospholipids to produce the signaling molecule lysophosphatidic acid (LPA) in extracellular fluids (PubMed:15769751, PubMed:26371182, PubMed:27754931, PubMed:14500380, PubMed:12354767,). Major substrate is lysophosphatidylcholine (PubMed:12176993, PubMed:27754931, PubMed:14500380). Also can act on sphingosylphosphorylcholine producing sphingosine-1-phosphate, a modulator of cell motility (PubMed:14500380). Can hydrolyze, in vitro, bis-pNPP, to some extent pNP-TMP, and barely ATP (PubMed:15769751, PubMed:12176993). Involved in several motility-related processes such as angiogenesis and neurite outgrowth. Acts as an angiogenic factor by stimulating migration of smooth muscle cells and microtubule formation (PubMed:11559573). Stimulates migration of melanoma cells, probably via a pertussis toxin-sensitive G protein (PubMed:1733949). May have a role in induction of parturition (PubMed:12176993). Possible involvement in cell proliferation and adipose tissue development (Probable). Tumor cell motility-stimulating factor (PubMed:1733949, PubMed:11559573). Required for LPA production in activated platelets, cleaves the sn-1 lysophospholipids to generate sn-1 lysophosphatidic acids containing predominantly 18:2 and 20:4 fatty acids (PubMed:21393252). Shows a preference for the sn-1 to the sn-2 isomer of 1-O-alkyl-sn-glycero-3-phosphocholine (lyso-PAF) (PubMed:21393252). {ECO:0000269|PubMed:11559573, ECO:0000269|PubMed:12176993, ECO:0000269|PubMed:12354767, ECO:0000269|PubMed:14500380, ECO:0000269|PubMed:15769751, ECO:0000269|PubMed:1733949, ECO:0000269|PubMed:21240271, ECO:0000269|PubMed:21393252, ECO:0000269|PubMed:26371182, ECO:0000269|PubMed:27754931, ECO:0000305|PubMed:15700135}.
Ensembl transtripts involved in fusion geneENST idsENST00000346997, ENST00000351936, 
ENST00000356226, ENST00000357555, 
ENST00000358487, ENST00000360144, 
ENST00000369056, ENST00000369059, 
ENST00000369061, ENST00000457416, 
ENST00000478859, ENST00000359354, 
ENST00000369060, ENST00000490349, 
ENST00000075322, ENST00000518109, 
ENST00000522167, ENST00000522826, 
ENST00000259486, ENST00000427067, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score24 X 20 X 12=576010 X 9 X 6=540
# samples 3811
** MAII scorelog2(38/5760*10)=-3.92199748799873
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(11/540*10)=-2.29545588352617
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: FGFR2 [Title/Abstract] AND ENPP2 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: FGFR2 [Title/Abstract] AND ENPP2 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)FGFR2(123274637)-ENPP2(120650767), # samples:3
Anticipated loss of major functional domain due to fusion event.FGFR2-ENPP2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
FGFR2-ENPP2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
FGFR2-ENPP2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
FGFR2-ENPP2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
FGFR2-ENPP2 seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF.
FGFR2-ENPP2 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
FGFR2-ENPP2 seems lost the major protein functional domain in Hgene partner, which is a kinase due to the frame-shifted ORF.
FGFR2-ENPP2 seems lost the major protein functional domain in Tgene partner, which is a cell metabolism gene due to the frame-shifted ORF.
FGFR2-ENPP2 seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneFGFR2

GO:0008284

positive regulation of cell proliferation

8663044

HgeneFGFR2

GO:0008543

fibroblast growth factor receptor signaling pathway

8663044|15629145

HgeneFGFR2

GO:0018108

peptidyl-tyrosine phosphorylation

15629145|16844695

HgeneFGFR2

GO:0046777

protein autophosphorylation

15629145

TgeneENPP2

GO:0009395

phospholipid catabolic process

15280042|26371182

TgeneENPP2

GO:0030149

sphingolipid catabolic process

14500380

TgeneENPP2

GO:0030334

regulation of cell migration

1733949

TgeneENPP2

GO:0034638

phosphatidylcholine catabolic process

21240271

TgeneENPP2

GO:0050731

positive regulation of peptidyl-tyrosine phosphorylation

18054784



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr10:123274637/chr8:120650767)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across FGFR2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across ENPP2 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000346997FGFR2chr10123274637-ENST00000259486ENPP2chr8120650767-444312931240071331
ENST00000346997FGFR2chr10123274637-ENST00000427067ENPP2chr8120650767-436212931239261304
ENST00000369061FGFR2chr10123274630-ENST00000259486ENPP2chr8120650767-425111014838151255
ENST00000369061FGFR2chr10123274630-ENST00000427067ENPP2chr8120650767-417011014837341228
ENST00000346997FGFR2chr10123274630-ENST00000259486ENPP2chr8120650767-444312931240071331
ENST00000346997FGFR2chr10123274630-ENST00000427067ENPP2chr8120650767-436212931239261304
ENST00000369056FGFR2chr10123274630-ENST00000259486ENPP2chr8120650767-446413142440281334
ENST00000369056FGFR2chr10123274630-ENST00000427067ENPP2chr8120650767-438313142439471307
ENST00000369061FGFR2chr10123274631-ENST00000259486ENPP2chr8120650767-425111014838151255
ENST00000369061FGFR2chr10123274631-ENST00000427067ENPP2chr8120650767-417011014837341228
ENST00000346997FGFR2chr10123274631-ENST00000259486ENPP2chr8120650767-444312931240071331
ENST00000346997FGFR2chr10123274631-ENST00000427067ENPP2chr8120650767-436212931239261304
ENST00000369056FGFR2chr10123274631-ENST00000259486ENPP2chr8120650767-446413142440281334
ENST00000369056FGFR2chr10123274631-ENST00000427067ENPP2chr8120650767-438313142439471307

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000346997ENST00000259486FGFR2chr10123274637-ENPP2chr8120650767-0.0003688350.99963117
ENST00000346997ENST00000427067FGFR2chr10123274637-ENPP2chr8120650767-0.0004770950.9995229
ENST00000369061ENST00000259486FGFR2chr10123274630-ENPP2chr8120650767-0.0004859660.999514
ENST00000369061ENST00000427067FGFR2chr10123274630-ENPP2chr8120650767-0.0006039950.99939597
ENST00000346997ENST00000259486FGFR2chr10123274630-ENPP2chr8120650767-0.0003688350.99963117
ENST00000346997ENST00000427067FGFR2chr10123274630-ENPP2chr8120650767-0.0004770950.9995229
ENST00000369056ENST00000259486FGFR2chr10123274630-ENPP2chr8120650767-0.0003415630.99965847
ENST00000369056ENST00000427067FGFR2chr10123274630-ENPP2chr8120650767-0.0003398390.99966013
ENST00000369061ENST00000259486FGFR2chr10123274631-ENPP2chr8120650767-0.0004859660.999514
ENST00000369061ENST00000427067FGFR2chr10123274631-ENPP2chr8120650767-0.0006039950.99939597
ENST00000346997ENST00000259486FGFR2chr10123274631-ENPP2chr8120650767-0.0003688350.99963117
ENST00000346997ENST00000427067FGFR2chr10123274631-ENPP2chr8120650767-0.0004770950.9995229
ENST00000369056ENST00000259486FGFR2chr10123274631-ENPP2chr8120650767-0.0003415630.99965847
ENST00000369056ENST00000427067FGFR2chr10123274631-ENPP2chr8120650767-0.0003398390.99966013

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for FGFR2-ENPP2

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
FGFR2chr10123274630ENPP2chr81206507671101351KLTKRIPLRRQVTIISLFTFAVGVNI
FGFR2chr10123274630ENPP2chr81206507671293427VHKLTKRIPLRRQIISLFTFAVGVNI
FGFR2chr10123274630ENPP2chr81206507671314430KLTKRIPLRRQVTIISLFTFAVGVNI
FGFR2chr10123274631ENPP2chr81206507671101351KLTKRIPLRRQVTIISLFTFAVGVNI
FGFR2chr10123274631ENPP2chr81206507671293427VHKLTKRIPLRRQIISLFTFAVGVNI
FGFR2chr10123274631ENPP2chr81206507671314430KLTKRIPLRRQVTIISLFTFAVGVNI
FGFR2chr10123274637ENPP2chr81206507671293427VHKLTKRIPLRRQIISLFTFAVGVNI

Top

Potential FusionNeoAntigen Information of FGFR2-ENPP2 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
FGFR2-ENPP2_123274630_120650767.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:05RRQIISLF0.99990.89831018
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:02RRQIISLF0.99990.60021018
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:04RRQIISLF0.99990.7881018
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B14:02LRRQIISL0.9990.5661917
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B14:01LRRQIISL0.9990.5661917
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B08:09IPLRRQII0.99580.6548715
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:03RQVTIISL0.97810.6106917
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B39:13RQVTIISL0.9780.7487917
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B13:01RQVTIISL0.97250.8681917
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B52:01RQVTIISL0.52530.5951917
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B27:04RRQVTIISL0.99990.7103817
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B27:05RRQVTIISL0.99990.8234817
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:05KRIPLRRQI0.99970.6013514
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:04KRIPLRRQI0.99960.6151514
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:01RQVTIISLF0.99920.7757918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B15:01RQIISLFTF0.99810.81291120
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:04LRRQIISLF0.99710.8125918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:05LRRQIISLF0.99710.9262918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:02LRRQIISLF0.9970.6934918
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B08:01IPLRRQVTI0.99560.599514
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B27:04RQVTIISLF0.99520.6816918
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B39:06RRQVTIISL0.99460.5563817
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B39:01RRQVTIISL0.99340.711817
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:04RQIISLFTF0.99330.67911120
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B08:09IPLRRQVTI0.99320.7381514
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:02RQIISLFTF0.9930.50811120
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B58:01VTIISLFTF0.99110.58661120
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:17VTIISLFTF0.99090.71971120
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B57:01VTIISLFTF0.98660.80571120
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B14:02IPLRRQVTI0.98640.842514
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B14:01IPLRRQVTI0.98640.842514
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B38:02RRQVTIISL0.98140.8067817
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B58:02VTIISLFTF0.98020.66221120
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B38:01RRQVTIISL0.97840.8001817
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:25RQVTIISLF0.97110.8567918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-A32:13RQIISLFTF0.9690.78341120
FGFR2-ENPP2chr10123274630chr81206507671314HLA-A32:13RQVTIISLF0.96620.8145918
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B57:03VTIISLFTF0.96350.82691120
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B15:25RQIISLFTF0.95060.8561120
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:03RQVTIISLF0.91880.5907918
FGFR2-ENPP2chr10123274630chr81206507671314HLA-A32:13VTIISLFTF0.90860.7381120
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B35:03IPLRRQVTI0.89860.8138514
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B15:03RQIISLFTF0.85030.60851120
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B13:01RQVTIISLF0.81490.83918
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B35:02IPLRRQVTI0.81270.9218514
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B35:04IPLRRQVTI0.81270.9218514
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B13:01RQIISLFTF0.77370.74641120
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B39:13RQIISLFTF0.47630.78981120
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B39:13RQVTIISLF0.43590.7273918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B52:01RQIISLFTF0.08510.55591120
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B52:01RQVTIISLF0.04380.5961918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:05RRQIISLFTF10.80751020
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B27:05RRQVTIISLF10.7866818
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B27:04RRQVTIISLF0.99990.6704818
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:04RRQIISLFTF0.99990.67511020
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B08:09IPLRRQIISL0.98730.5703717
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B57:03QVTIISLFTF0.95730.89091020
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:01RRQVTIISLF0.92210.7599818
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B13:01RRQVTIISLF0.66860.837818
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B27:04KRIPLRRQVTI0.99990.5322314
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B27:02LRRQVTIISLF0.99980.5161718
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:02LRRQIISLFTF0.99970.6920
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:01RQVTIISLFTF0.99930.7623920
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B57:03RQVTIISLFTF0.94830.8902920
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B13:01RQVTIISLFTF0.90970.8408920
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C07:95RRQIISLF0.99970.57061018
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C07:05RRQIISLF0.99960.94831018
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C07:05LRRQIISL0.99910.9416917
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:03RRQIISLF0.99610.91351018
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:04RQVTIISL0.99360.8292917
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B39:12LRRQIISL0.99210.7977917
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B39:08RQVTIISL0.98390.6153917
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B27:14RRQVTIISL0.99990.7633817
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:14KRIPLRRQI0.99960.5179514
FGFR2-ENPP2chr10123274630chr81206507671314HLA-C07:05RRQVTIISL0.99820.944817
FGFR2-ENPP2chr10123274630chr81206507671314HLA-C07:13RRQVTIISL0.99670.8491817
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:14LRRQIISLF0.99660.8538918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:14RRQIISLFT0.99620.74231019
FGFR2-ENPP2chr10123274630chr81206507671314HLA-C07:29RRQVTIISL0.99610.8579817
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B27:03RRQVTIISL0.99550.8428817
FGFR2-ENPP2chr10123274630chr81206507671314HLA-C07:27RRQVTIISL0.99540.9183817
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B42:02IPLRRQVTI0.99490.5845514
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B42:01IPLRRQVTI0.99480.576514
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:07RQVTIISLF0.99390.5697918
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B39:12RRQVTIISL0.99290.7223817
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B15:07RQIISLFTF0.99040.59391120
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:04RQVTIISLF0.99030.7945918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C07:05LRRQIISLF0.98970.9494918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:03KRIPLRRQI0.98830.6232514
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C07:95KRIPLRRQI0.9870.8207514
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C07:95LRRQIISLF0.98690.5871918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B15:04RQIISLFTF0.98320.81061120
FGFR2-ENPP2chr10123274630chr81206507671314HLA-C07:46RRQVTIISL0.98260.7444817
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C07:27LRRQIISLF0.97680.9301918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C07:27KRIPLRRQI0.97620.9687514
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C07:05KRIPLRRQI0.97330.9665514
FGFR2-ENPP2chr10123274630chr81206507671314HLA-C07:67RRQVTIISL0.97030.8937817
FGFR2-ENPP2chr10123274630chr81206507671314HLA-C07:80RRQVTIISL0.97030.8937817
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B07:12IPLRRQVTI0.96530.537514
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B39:05RRQVTIISL0.95860.6951817
FGFR2-ENPP2chr10123274630chr81206507671314HLA-C07:10RRQVTIISL0.94610.9332817
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C07:46KRIPLRRQI0.93650.9247514
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C07:29KRIPLRRQI0.93380.962514
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C07:13KRIPLRRQI0.91840.9418514
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:03LRRQIISLF0.9010.9343918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C07:19KRIPLRRQI0.89960.8316514
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C07:80KRIPLRRQI0.89330.9606514
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C07:67KRIPLRRQI0.89330.9606514
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C07:10KRIPLRRQI0.88540.9521514
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C07:80LRRQIISLF0.85190.9012918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C07:67LRRQIISLF0.85190.9012918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C07:19LRRQIISLF0.85090.5161918
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B14:03IPLRRQVTI0.84330.8761514
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C07:10LRRQIISLF0.83730.9437918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C07:46LRRQIISLF0.83610.7658918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B15:05RQIISLFTF0.82830.67971120
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B35:12IPLRRQVTI0.81270.9218514
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:05RQVTIISLF0.80140.7078918
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B39:10IPLRRQVTI0.41860.9531514
FGFR2-ENPP2chr10123274630chr81206507671314HLA-C12:16RRQVTIISL0.39960.9466817
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C12:16LRRQIISLF0.32880.9628918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C01:30RIPLRRQII0.13630.9378615
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C01:17RIPLRRQII0.08620.9363615
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C12:16KRIPLRRQI0.02490.9676514
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B27:14RRQVTIISLF10.7302818
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:14RRQIISLFTF10.74511020
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B27:03RRQVTIISLF0.99930.81818
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:03RRQIISLFTF0.99930.83111020
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B07:12IPLRRQIISL0.98880.5354717
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:07RRQVTIISLF0.89570.5756818
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:07RQVTIISLFTF0.99470.5566920
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:08RRQIISLF0.99990.79841018
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:10RRQIISLF0.99990.88771018
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C07:01RRQIISLF0.99970.52951018
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:68RQVTIISL0.99770.5241917
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:73RQVTIISL0.99110.6549917
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B39:02RQVTIISL0.9910.7479917
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:30RQVTIISL0.98550.6556917
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B27:08RRQVTIISL0.99990.6855817
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B27:10RRQVTIISL0.99990.8503817
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B27:06RRQVTIISL0.99990.6794817
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B27:09RRQVTIISL0.99980.7531817
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:06KRIPLRRQI0.99960.6359514
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:10KRIPLRRQI0.99960.7946514
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:27RQVTIISLF0.99930.8047918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:09KRIPLRRQI0.99930.5913514
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:135RQVTIISLF0.99930.7754918
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:33RQVTIISLF0.99920.7757918
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:34RQVTIISLF0.99920.7757918
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:125RQVTIISLF0.99920.7757918
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:50RQVTIISLF0.99880.8079918
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:24RQVTIISLF0.99850.7831918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B15:135RQIISLFTF0.99820.81011120
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B15:34RQIISLFTF0.99810.81291120
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B15:33RQIISLFTF0.99810.81291120
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B15:27RQIISLFTF0.99810.82781120
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B15:125RQIISLFTF0.99810.81291120
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:08LRRQIISLF0.9970.8262918
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:12RQVTIISLF0.99680.7463918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:10LRRQIISLF0.99670.9082918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B15:24RQIISLFTF0.99640.78321120
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:06LRRQIISLF0.99620.797918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B15:50RQIISLFTF0.99610.90641120
FGFR2-ENPP2chr10123274630chr81206507671314HLA-C07:17RRQVTIISL0.99580.9484817
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B27:06RQVTIISLF0.99560.6472918
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B08:18IPLRRQVTI0.99560.599514
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:06RQIISLFTF0.99480.63671120
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B39:02RRQVTIISL0.99420.7585817
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B39:31RRQVTIISL0.99380.7184817
FGFR2-ENPP2chr10123274630chr81206507671293HLA-A32:01RQIISLFTF0.99250.90011120
FGFR2-ENPP2chr10123274630chr81206507671314HLA-A32:01RQVTIISLF0.99220.8203918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:08RQIISLFTF0.99140.67841120
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:35RQVTIISLF0.99130.7668918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C07:01KRIPLRRQI0.99110.8041514
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C07:01LRRQIISLF0.99020.5489918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B15:12RQIISLFTF0.98880.76241120
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:53RQVTIISLF0.98810.7377918
FGFR2-ENPP2chr10123274630chr81206507671314HLA-C06:08RRQVTIISL0.98770.9897817
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B15:35RQIISLFTF0.98720.80691120
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B57:10VTIISLFTF0.98660.80571120
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B27:09RQVTIISLF0.98570.7177918
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B57:02VTIISLFTF0.98070.67791120
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:09RQIISLFTF0.98060.69011120
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B38:05RRQVTIISL0.97840.8001817
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:39RQVTIISLF0.97330.6993918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:09LRRQIISLF0.97330.8813918
FGFR2-ENPP2chr10123274630chr81206507671314HLA-C07:02RRQVTIISL0.97030.8937817
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B15:53RQIISLFTF0.97020.7951120
FGFR2-ENPP2chr10123274630chr81206507671314HLA-C07:22RRQVTIISL0.96080.6148817
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:54RQVTIISLF0.95340.7178918
FGFR2-ENPP2chr10123274630chr81206507671314HLA-C07:04RRQVTIISL0.95250.9389817
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B15:39RQIISLFTF0.95210.71331120
FGFR2-ENPP2chr10123274630chr81206507671314HLA-A32:01VTIISLFTF0.94140.85161120
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B15:68RQIISLFTF0.94080.52281120
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:73RQVTIISLF0.94020.613918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B15:54RQIISLFTF0.93620.75231120
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B35:13IPLRRQVTI0.92330.8182514
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:13RQVTIISLF0.91030.5752918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C07:02KRIPLRRQI0.89330.9606514
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B15:73RQIISLFTF0.87750.64921120
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C07:22LRRQIISLF0.87610.7237918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C06:08KRIPLRRQI0.85640.9905514
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C07:02LRRQIISLF0.85190.9012918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B15:20RQIISLFTF0.83190.76141120
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B08:12IPLRRQVTI0.82030.8401514
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B35:09IPLRRQVTI0.81270.9218514
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B35:28RQIISLFTF0.81080.76271120
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C07:22KRIPLRRQI0.80170.8469514
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:20RQVTIISLF0.79450.7877918
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:30RQVTIISLF0.79190.6687918
FGFR2-ENPP2chr10123274630chr81206507671314HLA-C06:06RRQVTIISL0.77430.987817
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B15:30RQIISLFTF0.76810.76421120
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B35:28RQVTIISLF0.75930.7905918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B48:02RQIISLFTF0.72160.7211120
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C06:08LRRQIISLF0.71420.9945918
FGFR2-ENPP2chr10123274630chr81206507671314HLA-C02:10RQVTIISLF0.70920.9674918
FGFR2-ENPP2chr10123274630chr81206507671314HLA-C02:02RQVTIISLF0.70920.9674918
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B48:02RQVTIISLF0.67010.7553918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C07:04KRIPLRRQI0.65870.9576514
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B39:02RQIISLFTF0.62350.81120
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B39:02RQVTIISLF0.60470.7346918
FGFR2-ENPP2chr10123274630chr81206507671314HLA-C03:67RRQVTIISL0.57850.9688817
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:68RRQVTIISL0.5480.5366817
FGFR2-ENPP2chr10123274630chr81206507671314HLA-C06:17RRQVTIISL0.53960.9896817
FGFR2-ENPP2chr10123274630chr81206507671314HLA-C06:02RRQVTIISL0.53960.9896817
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B67:01IPLRRQVTI0.48670.7547514
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C06:06KRIPLRRQI0.29270.992514
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C06:02LRRQIISLF0.17570.9949918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C06:17LRRQIISLF0.17570.9949918
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C01:02RIPLRRQII0.06720.9364615
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C06:17KRIPLRRQI0.04880.9955514
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C06:02KRIPLRRQI0.04880.9955514
FGFR2-ENPP2chr10123274630chr81206507671293HLA-C01:03RIPLRRQII0.03660.9307615
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:08RRQIISLFTF10.69171020
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B27:10RRQVTIISLF10.8359818
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:10RRQIISLFTF0.99990.82021020
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:06RRQIISLFTF0.99990.61881020
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B27:08RRQVTIISLF0.99990.6366818
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B27:06RRQVTIISLF0.99980.635818
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:09RRQIISLFTF0.99980.70011020
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B27:09RRQVTIISLF0.99960.6951818
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B27:06KRIPLRRQII0.9990.5933515
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B27:06LRRQVTIISL0.99870.7013717
FGFR2-ENPP2chr10123274630chr81206507671314HLA-C07:22RRQVTIISLF0.99590.6014818
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:54RRQVTIISLF0.95950.7107818
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B15:68RRQIISLFTF0.95860.55241020
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B08:12IPLRRQIISL0.94670.694717
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:33RRQVTIISLF0.92210.7599818
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:125RRQVTIISLF0.92210.7599818
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:34RRQVTIISLF0.92210.7599818
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:53RRQVTIISLF0.90930.7296818
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:135RRQVTIISLF0.9070.759818
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:35RRQVTIISLF0.90640.7583818
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:50RRQVTIISLF0.90070.7867818
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:24RRQVTIISLF0.8920.7721818
FGFR2-ENPP2chr10123274630chr81206507671293HLA-B67:01IPLRRQIISL0.7030.6816717
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B27:06KRIPLRRQVTI0.99990.5607314
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B27:10KRIPLRRQVTI0.99990.6418314
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:50RQVTIISLFTF0.99930.8048920
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:33RQVTIISLFTF0.99930.7623920
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:34RQVTIISLFTF0.99930.7623920
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:125RQVTIISLFTF0.99930.7623920
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:27RQVTIISLFTF0.99920.7987920
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:135RQVTIISLFTF0.99920.763920
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:24RQVTIISLFTF0.99870.7545920
FGFR2-ENPP2chr10123274630chr81206507671314HLA-B15:35RQVTIISLFTF0.99140.7686920

Top

Potential FusionNeoAntigen Information of FGFR2-ENPP2 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of FGFR2-ENPP2

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
6791PLRRQVTIISLFTFFGFR2ENPP2chr10123274630chr81206507671314
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
7943RIPLRRQIISLFTFFGFR2ENPP2chr10123274630chr81206507671293

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of FGFR2-ENPP2

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN6791PLRRQVTIISLFTF-7.15543-7.26883
HLA-B14:023BVN6791PLRRQVTIISLFTF-4.77435-5.80965
HLA-B52:013W396791PLRRQVTIISLFTF-6.80875-6.92215
HLA-B52:013W396791PLRRQVTIISLFTF-4.20386-5.23916
HLA-A11:014UQ26791PLRRQVTIISLFTF-7.5194-8.5547
HLA-A11:014UQ26791PLRRQVTIISLFTF-6.9601-7.0735
HLA-A24:025HGA6791PLRRQVTIISLFTF-7.52403-7.63743
HLA-A24:025HGA6791PLRRQVTIISLFTF-5.82433-6.85963
HLA-B27:056PYJ6791PLRRQVTIISLFTF-3.28285-4.31815
HLA-B44:053DX86791PLRRQVTIISLFTF-5.91172-6.94702
HLA-B44:053DX86791PLRRQVTIISLFTF-4.24346-4.35686
HLA-B14:023BVN7943RIPLRRQIISLFTF-7.14368-7.25548
HLA-B14:023BVN7943RIPLRRQIISLFTF-6.90724-7.95034
HLA-B52:013W397943RIPLRRQIISLFTF-7.67666-8.71976
HLA-B52:013W397943RIPLRRQIISLFTF-5.5221-5.6339
HLA-A11:014UQ27943RIPLRRQIISLFTF-8.37369-9.41679
HLA-A11:014UQ27943RIPLRRQIISLFTF-6.26273-6.37453
HLA-A24:025HGA7943RIPLRRQIISLFTF-7.6158-8.6589
HLA-A24:025HGA7943RIPLRRQIISLFTF-5.36701-5.47881
HLA-B44:053DX87943RIPLRRQIISLFTF-8.09865-8.21045
HLA-B44:053DX87943RIPLRRQIISLFTF-5.97829-7.02139

Top

Vaccine Design for the FusionNeoAntigens of FGFR2-ENPP2

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
FGFR2-ENPP2chr10123274630chr81206507671018RRQIISLFCGGAGACAGATAATATCCCTGTTC
FGFR2-ENPP2chr10123274630chr81206507671019RRQIISLFTCGGAGACAGATAATATCCCTGTTCACT
FGFR2-ENPP2chr10123274630chr81206507671020QVTIISLFTFCAGGTAACAATAATATCCCTGTTCACTTTT
FGFR2-ENPP2chr10123274630chr81206507671020RRQIISLFTFCGGAGACAGATAATATCCCTGTTCACTTTT
FGFR2-ENPP2chr10123274630chr81206507671120RQIISLFTFAGACAGATAATATCCCTGTTCACTTTT
FGFR2-ENPP2chr10123274630chr81206507671120VTIISLFTFGTAACAATAATATCCCTGTTCACTTTT
FGFR2-ENPP2chr10123274630chr8120650767314KRIPLRRQVTIAAACGTATCCCCCTGCGGAGACAGGTAACAATA
FGFR2-ENPP2chr10123274630chr8120650767514IPLRRQVTIATCCCCCTGCGGAGACAGGTAACAATA
FGFR2-ENPP2chr10123274630chr8120650767514KRIPLRRQIAAACGTATCCCCCTGCGGAGACAGATA
FGFR2-ENPP2chr10123274630chr8120650767515KRIPLRRQIIAAACGTATCCCCCTGCGGAGACAGATAATA
FGFR2-ENPP2chr10123274630chr8120650767615RIPLRRQIICGTATCCCCCTGCGGAGACAGATAATA
FGFR2-ENPP2chr10123274630chr8120650767715IPLRRQIIATCCCCCTGCGGAGACAGATAATA
FGFR2-ENPP2chr10123274630chr8120650767717IPLRRQIISLATCCCCCTGCGGAGACAGATAATATCCCTG
FGFR2-ENPP2chr10123274630chr8120650767717LRRQVTIISLCTGCGGAGACAGGTAACAATAATATCCCTG
FGFR2-ENPP2chr10123274630chr8120650767718LRRQVTIISLFCTGCGGAGACAGGTAACAATAATATCCCTGTTC
FGFR2-ENPP2chr10123274630chr8120650767817RRQVTIISLCGGAGACAGGTAACAATAATATCCCTG
FGFR2-ENPP2chr10123274630chr8120650767818RRQVTIISLFCGGAGACAGGTAACAATAATATCCCTGTTC
FGFR2-ENPP2chr10123274630chr8120650767917LRRQIISLCTGCGGAGACAGATAATATCCCTG
FGFR2-ENPP2chr10123274630chr8120650767917RQVTIISLAGACAGGTAACAATAATATCCCTG
FGFR2-ENPP2chr10123274630chr8120650767918LRRQIISLFCTGCGGAGACAGATAATATCCCTGTTC
FGFR2-ENPP2chr10123274630chr8120650767918RQVTIISLFAGACAGGTAACAATAATATCCCTGTTC
FGFR2-ENPP2chr10123274630chr8120650767920LRRQIISLFTFCTGCGGAGACAGATAATATCCCTGTTCACTTTT
FGFR2-ENPP2chr10123274630chr8120650767920RQVTIISLFTFAGACAGGTAACAATAATATCCCTGTTCACTTTT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of FGFR2-ENPP2

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
BRCAFGFR2-ENPP2chr10123274630ENST00000346997chr8120650767ENST00000259486TCGA-LD-A7W5
BRCAFGFR2-ENPP2chr10123274630ENST00000369056chr8120650767ENST00000259486TCGA-LD-A7W5

Top

Potential target of CAR-T therapy development for FGFR2-ENPP2

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
HgeneFGFR2chr10:123274630chr8:120650767ENST00000346997-817378_398427820.0TransmembraneHelical
HgeneFGFR2chr10:123274630chr8:120650767ENST00000351936-918378_398427786.0TransmembraneHelical
HgeneFGFR2chr10:123274630chr8:120650767ENST00000358487-918378_398429822.0TransmembraneHelical
HgeneFGFR2chr10:123274630chr8:120650767ENST00000369056-817378_398430770.0TransmembraneHelical
HgeneFGFR2chr10:123274630chr8:120650767ENST00000457416-918378_398430823.0TransmembraneHelical
HgeneFGFR2chr10:123274631chr8:120650767ENST00000346997-817378_398427820.0TransmembraneHelical
HgeneFGFR2chr10:123274631chr8:120650767ENST00000351936-918378_398427786.0TransmembraneHelical
HgeneFGFR2chr10:123274631chr8:120650767ENST00000358487-918378_398429822.0TransmembraneHelical
HgeneFGFR2chr10:123274631chr8:120650767ENST00000369056-817378_398430770.0TransmembraneHelical
HgeneFGFR2chr10:123274631chr8:120650767ENST00000457416-918378_398430823.0TransmembraneHelical
HgeneFGFR2chr10:123274637chr8:120650767ENST00000346997-817378_398427820.0TransmembraneHelical
HgeneFGFR2chr10:123274637chr8:120650767ENST00000351936-918378_398427786.0TransmembraneHelical

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to FGFR2-ENPP2

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to FGFR2-ENPP2

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
HgeneFGFR2C2931196Craniofacial dysostosis type 123CTD_human;GENOMICS_ENGLAND;UNIPROT
HgeneFGFR2C0220658Pfeiffer Syndrome21CTD_human;GENOMICS_ENGLAND;UNIPROT
HgeneFGFR2C0001193Apert syndrome19CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
HgeneFGFR2C0795998JACKSON-WEISS SYNDROME10CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
HgeneFGFR2C0175699Saethre-Chotzen Syndrome8CTD_human;GENOMICS_ENGLAND;ORPHANET
HgeneFGFR2C1852406Cutis Gyrata Syndrome of Beare And Stevenson8CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
HgeneFGFR2C2936791Antley-Bixler Syndrome, Autosomal Dominant7CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
HgeneFGFR2C1510455Acrocephalosyndactylia6CTD_human;ORPHANET
HgeneFGFR2C0265269Lacrimoauriculodentodigital syndrome5CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
HgeneFGFR2C0010278Craniosynostosis4CTD_human;GENOMICS_ENGLAND
HgeneFGFR2C1863389Apert-Crouzon Disease4CTD_human
HgeneFGFR2C1865070SCAPHOCEPHALY, MAXILLARY RETRUSION, AND MENTAL RETARDATION4CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
HgeneFGFR2C0006142Malignant neoplasm of breast3CTD_human;UNIPROT
HgeneFGFR2C0030044Acrocephaly3CTD_human
HgeneFGFR2C0036341Schizophrenia3PSYGENET
HgeneFGFR2C0221356Brachycephaly3CTD_human
HgeneFGFR2C0265534Scaphycephaly3CTD_human
HgeneFGFR2C0265535Trigonocephaly3CTD_human
HgeneFGFR2C0376634Craniofacial Abnormalities3CTD_human
HgeneFGFR2C0678222Breast Carcinoma3CTD_human
HgeneFGFR2C1257931Mammary Neoplasms, Human3CTD_human
HgeneFGFR2C1458155Mammary Neoplasms3CTD_human
HgeneFGFR2C1833340Synostotic Posterior Plagiocephaly3CTD_human
HgeneFGFR2C1860819Metopic synostosis3CTD_human
HgeneFGFR2C2931150Synostotic Anterior Plagiocephaly3CTD_human
HgeneFGFR2C3281247BENT BONE DYSPLASIA SYNDROME3CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
HgeneFGFR2C4551902Craniosynostosis, Type 13CTD_human
HgeneFGFR2C4704874Mammary Carcinoma, Human3CTD_human
HgeneFGFR2C0008925Cleft Palate2CTD_human
HgeneFGFR2C0011570Mental Depression2PSYGENET
HgeneFGFR2C0011581Depressive disorder2PSYGENET
HgeneFGFR2C0024623Malignant neoplasm of stomach2CGI;CTD_human
HgeneFGFR2C0038356Stomach Neoplasms2CGI;CTD_human
HgeneFGFR2C1708349Hereditary Diffuse Gastric Cancer2CTD_human
HgeneFGFR2C1837218Cleft palate, isolated2CTD_human
HgeneFGFR2C0000772Multiple congenital anomalies1CTD_human
HgeneFGFR2C0003090Ankylosis1CTD_human
HgeneFGFR2C0005586Bipolar Disorder1PSYGENET
HgeneFGFR2C0008924Cleft upper lip1CTD_human
HgeneFGFR2C0010273Craniofacial Dysostosis1CTD_human
HgeneFGFR2C0011757Developmental Coordination Disorder1CTD_human
HgeneFGFR2C0014170Endometrial Neoplasms1CTD_human
HgeneFGFR2C0018553Hamartoma Syndrome, Multiple1CTD_human
HgeneFGFR2C0020796Profound Mental Retardation1CTD_human
HgeneFGFR2C0023890Liver Cirrhosis1CTD_human
HgeneFGFR2C0024121Lung Neoplasms1CTD_human
HgeneFGFR2C0025363Mental Retardation, Psychosocial1CTD_human
HgeneFGFR2C0026613Motor Skills Disorders1CTD_human
HgeneFGFR2C0033975Psychotic Disorders1PSYGENET
HgeneFGFR2C0037268Skin Abnormalities1CTD_human
HgeneFGFR2C0037274Dermatologic disorders1CTD_human
HgeneFGFR2C0038219Status Dysraphicus1CTD_human
HgeneFGFR2C0040427Tooth Abnormalities1CTD_human
HgeneFGFR2C0080178Spina Bifida1CTD_human
HgeneFGFR2C0152423Congenital small ears1GENOMICS_ENGLAND
HgeneFGFR2C0206698Cholangiocarcinoma1CTD_human
HgeneFGFR2C0206762Limb Deformities, Congenital1CTD_human
HgeneFGFR2C0239946Fibrosis, Liver1CTD_human
HgeneFGFR2C0242379Malignant neoplasm of lung1CTD_human
HgeneFGFR2C0265326Bannayan-Riley-Ruvalcaba Syndrome1CTD_human
HgeneFGFR2C0266508Rachischisis1CTD_human
HgeneFGFR2C0345905Intrahepatic Cholangiocarcinoma1CTD_human
HgeneFGFR2C0349204Nonorganic psychosis1PSYGENET
HgeneFGFR2C0391826Lhermitte-Duclos disease1CTD_human
HgeneFGFR2C0476089Endometrial Carcinoma1CGI;CTD_human
HgeneFGFR2C0524730Odontome1CTD_human
HgeneFGFR2C0699791Stomach Carcinoma1CGI;GENOMICS_ENGLAND
HgeneFGFR2C0917816Mental deficiency1CTD_human
HgeneFGFR2C1450010Plagiocephaly, Nonsynostotic1CTD_human
HgeneFGFR2C1860042Antley-Bixler Syndrome with Disordered Steroidogenesis1CTD_human
HgeneFGFR2C1867564SCAPHOCEPHALY AND AXENFELD-RIEGER ANOMALY1GENOMICS_ENGLAND
HgeneFGFR2C1959582PTEN Hamartoma Tumor Syndrome1CTD_human
HgeneFGFR2C2350233Antley-Bixler Syndrome Phenotype1CTD_human
HgeneFGFR2C3267076Familial scaphocephaly syndrome1GENOMICS_ENGLAND
HgeneFGFR2C3714756Intellectual Disability1CTD_human
HgeneFGFR2C3805278Extrahepatic Cholangiocarcinoma1CTD_human